U.S. markets closed

VBI Vaccines Inc. (VBIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7100-0.1850 (-6.39%)
At close: 4:00PM EDT

VBI Vaccines Inc.

222 Third Street
Suite 2241
Cambridge, MA 02142
United States
617 830 3031
http://www.vbivaccines.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees127

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey R. Baxter F.C.M.A., FCMAPres, CEO & Director736.13kN/A1961
Dr. David Evander AndersonChief Scientific Officer452.7kN/A1970
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.Chief Medical Officer488.2kN/A1955
Mr. Christopher McNultyCFO, Head of Bus. Devel. & DirectorN/AN/A1977
Nicole AndersonDirector of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Athena KartsaklisSr. VP of Fin., Chief Compliance Officer & Principal Financial OfficerN/AN/A1965
Ms. Nell BeattieChief Bus. OfficerN/AN/A1988
Mr. Avi MazaltovGlobal Head of Manufacturing & GM of SciVacN/AN/A1962
Mr. Misha NossovSr. VP of Market Access & CommercialN/AN/AN/A
Mr. T. Adam BuckleySr. VP of Bus. Devel.N/AN/A1976
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Corporate Governance

VBI Vaccines Inc.’s ISS Governance QualityScore as of April 1, 2021 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.